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DOI 10.1186/s12888-017-1577-7RESEARCH ARTICLE Open AccessEconomic evaluation of an experience
sampling method intervention in
depression compared with treatment as
usual using data from a randomized
controlled trial
Claudia J. P. Simons1,2*† , Marjan Drukker1†, Silvia Evers3,4, Ghislaine A. P. G. van Mastrigt3, Petra Höhn1,
Ingrid Kramer1,2, Frenk Peeters1, Philippe Delespaul1,5, Claudia Menne-Lothmann1, Jessica A. Hartmann6,
Jim van Os1,7,8 and Marieke Wichers9Abstract
Background: Experience sampling, a method for real-time self-monitoring of affective experiences, holds opportunities
for person-tailored treatment. By focussing on dynamic patterns of positive affect, experience sampling method
interventions (ESM-I) accommodate strategies to enhance personalized treatment of depression―at potentially low-costs.
This study aimed to investigate the cost-effectiveness of an experience sampling method intervention in patients with
depression, from a societal perspective.
Methods: Participants were recruited between January 2010 and February 2012 from out-patient mental health care
facilities in or near the Dutch cities of Eindhoven and Maastricht, and through local advertisements. Out-patients
diagnosed with major depression (n = 101) receiving pharmacotherapy were randomized into: (i) ESM-I consisting of six
weeks of ESM combined with weekly feedback regarding the individual’s positive affective experiences, (ii) six weeks of
ESM without feedback, or (iii) treatment as usual only. Alongside this randomised controlled trial, an economic evaluation
was conducted consisting of a cost-effectiveness and a cost-utility analysis, using Hamilton Depression Rating Scale
(HDRS) and quality adjusted life years (QALYs) as outcome, with willingness-to-pay threshold for a QALY set at €50,000
(based on Dutch guidelines for moderate severe to severe illnesses).
Results: The economic evaluation showed that ESM-I is an optimal strategy only when willingness to pay is around €3000
per unit HDRS and around €40,500 per QALY. ESM-I was the least favourable treatment when willingness to pay was lower
than €30,000 per QALY. However, at the €50,000 willingness-to-pay threshold, ESM-I was, with a 46% probability, the most
favourable treatment (base-case analysis). Sensitivity analyses confirmed the robustness of these results.
Conclusions: We may tentatively conclude that ESM-I is a cost-effective add-on intervention to pharmacotherapy in
outpatients with major depression.
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Depression consistently ranks high worldwide in terms of
disability [1–3] and societal costs due to health care con-
sumption and productivity loss [4]. In the Netherlands,
twelve-month prevalence of a depressive disorder is 5.2%
[5], health care costs are estimated at 1592 million euros
(1.8% of the total health care costs in 2011) [6], and disabil-
ity days are eight times higher compared with the general
population [7].
Because of the high disease burden of depression [1–5],
non-pharmacological interventions that can enhance (psy-
chopharmacological) treatment effects have the potential
to be cost-effective. Although clear evidence exists for the
effectiveness of combined pharmacotherapy with psycho-
therapy in the treatment of depression [8], face-to-face
psychological treatment is cost-intensive and may, unfor-
tunately, not be routinely available. Furthermore, it is esti-
mated that optimal use of cognitive-behavioural therapy,
counselling, and medication would lower the disease
burden of depression by 35% at most [9]. Thus, efforts to
improve the efficacy of pharmacotherapy combined with
psychotherapy are considered a priority.
Moment-to-moment ambulatory monitoring tools ―de-
signed to collect real-life data with easy and immediate
availability to both patients and professional caregivers―
pave the road for potential low-cost strategies to improve
and personalize mental health care. In particular, digitalized
experience sampling method (ESM) tools incorporating
repeated in-the-moment assessments of affective experience
and context seem to be an acceptable and feasible strategy
to provide unique person-tailored insights about affective
patterns in daily life [10–12]. Interventions using the Experi-
ence Sampling Method (Experience Sampling Method-
Interventions or ESM-I) may, therefore, provide possibilities
for mobile health (mHealth) interventions in depression
[13]. These interventions could be directed at increasing
positive affect, as ESM studies have shown that a high ability
to experience positive affect may predict development,
course, and recovery of depression [14–16].
A first effect study showed that ESM-I as add-on interven-
tion to psychopharmacological treatment, with feedback
focussed on positive affect, was efficacious in reducing
symptoms in patients with depression [17]. Although some
evidence exists that ambulatory self-assessments may be
cost-effective tools to manage health conditions [18, 19], to
our knowledge, no randomized controlled trials have investi-
gated the cost-effectiveness or cost-utility of any ESM-interventions in patients with depression. The present paper
presents a trial-based economic evaluation using data from
a randomised controlled trial. The purpose is to evaluate the
cost-effectiveness and cost-utility of ESM-I as add-on inter-
vention to psychopharmacological treatment as usual, from
a societal perspective. Because the hypothesis was that
ESM-derived feedback on daily life patterns is an essential
ingredient, ESM-I was compared with two control condi-
tions: (1) ESM self-monitoring without feedback, hereafter




For the current randomized controlled trial [17], partici-
pants were recruited between January 2010 and February
2012 from out-patient mental health care facilities in or
near the Dutch cities of Eindhoven and Maastricht, and
through local advertisements.
Patients were considered eligible if they were aged
between 18 and 65 years; diagnosed with major depression
according to DSM-IV [20] with current or residual symp-
toms (score of >7 on the 17-item Hamilton Depression
Rating Scale (HDRS) [21]); and treated with antidepressants
or mood stabilizers. Patients were excluded if they met
criteria for a non-affective psychotic disorder according to
DSM-IV or if they met criteria for a manic, hypo-manic or
mixed episode within the past month.
The study was approved by an institutional review board
(Medical Ethics Committee of Maastricht University Medical
Centre); all participants provided written informed consent
before enrolment. The trial was registered in the Netherlands
Trial Register (ID: NTR1974). The study was performed ac-
cording to the declaration of Helsinki. The original protocol
and a CONSORTchecklist are provided (see Additional files 1
and 2).
Treatment arms
A randomized controlled trial was conducted with three
treatment arms [17, 22]. All participants were asked to
complete a five-day ESM baseline assessment. After base-
line, patients were randomly allocated to the ESM-I,
pseudo-intervention, or control group. Randomization (allo-
cation ratio 1:1:1) was stratified for duration of pharmaco-
logical treatment (use of a particular antidepressant for
shorter vs. longer than 8 weeks prior to study entry) and
psychotherapy (yes/no). After all baseline assessments were
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sequentially numbered envelopes (prepared by an independ-
ent research coordinator) with a number sequence produced
by an electronic random sequence generator (http://
www.random.org), in blocks of six. Envelopes were opened
by the researcher (CS, PH, IK, CML, JH) or a research as-
sistant. Allocation was not blinded.
The ESM-I group participated in an ESM procedure
(three days per week over a six-week period; see below),
as addition to treatment as usual. This group received
weekly standardised feedback on personalized patterns of
positive affect. The pseudo-intervention group participated
in the same ESM procedure but received no feedback. The
control group received no additional intervention (treat-
ment as usual).
Experience sampling method
ESM was carried out in accordance with previous studies
[11, 23–25]: participants received a dedicated electronic
ESM device (‘PsyMate’, [26]) which emitted a signal at a
random moment in each of ten 90-min time blocks
between 07:30 am–10:30 pm, prompting participants to
fill in self-assessments including current positive and
negative affect, activities, and context (7-point Likert scale
ratings and forced-choice questions).
Intervention
For 6 consecutive weeks, ESM-I participants engaged in
ESM self-monitoring for three consecutive days within each
week. Each ESM week was followed by a face-to-face feed-
back session with one of the researchers (a psychologist or
psychiatrist, n= 5). These six sessions were held at the
participating mental health institutions or at Maastricht
University. In these sessions, the researcher provided the
participant verbal, graphical, and written feedback using the
participant’s ESM data, delivered according to a fixed
format, in a fixed order. Feedback showed actual levels of
positive affect in the context of daily life activities, events,
and social situations. In addition, changes in positive affect
level and depressive feelings over the course of the ESM
intervention were visualized (see [17] for examples). A
bullet-point summary report of the feedback was also given
to both the participant and his/her mental health profes-
sional using a fixed template.
The procedure in the pseudo-intervention group was
identical to the procedure in the ESM-I group except
that no feedback was given. In the pseudo-intervention
group, sessions were filled with an alternative activity
(an HDRS interview) to keep duration of contacts
equivalent to the ESM-I group.
Treatment as usual
Treatment as usual consisted of psychopharmacological
treatment as usual, either in primary or ambulatoryspecialized care, that is, patients were treated with anti-
depressants or mood stabilizers, either as stand-alone
treatment (e.g., with supportive counselling) or in com-
bination with psychotherapeutic treatment.
Procedure
Full screening occurred two weeks before randomization to
treatment. Severity of symptoms was assessed to determine
eligibility. In addition, self-report instruments were com-
pleted assessing costs and quality adjusted life years
(QALYs). One week later, the ESM procedure was
explained and all participants engaged in a five-day ESM
procedure after which baseline assessment took place. At
baseline, symptoms were assessed and participants were
subsequently randomized to treatment. Assessment of costs
and QALYs was not repeated at baseline, thus full screening
was used as a proxy for baseline. The 6-week intervention
period (week 1–6) was followed by an immediate post-
assessment, including symptom assessments and a five-day
ESM post-assessment (week 7), and a first follow-up (week
8). Other follow-up assessments were conducted at 4 (week
12), 8 (week 16), 12 weeks (week 20), and 24 weeks (week
32) after this first follow-up assessment. At follow-up,
symptoms (all follow-up assessments), costs, and QALYs
(follow-up at week 20 and 32) were assessed.Outcome measures
In the cost-effectiveness analyses, the Hamilton Depression
Rating Scale-17 (HDRS) [21] was used as the primary out-
come measure. The HDRS is a semi-structured interview
measuring the severity of depressive symptoms over the
past week. A higher HDRS score indicated higher levels of
depression. In the bootstrapping models (see Statistical
analysis paragraph), the HDRS was reversed (higher score
is better outcome, as is obligatory in economic evaluations).
Symptomatic remission was obtained using the HDRS;
participants with a HDRS score ≤ 7 were considered to be
in symptomatic remission [27].
In the cost-utility analyses, QALYs were used as the pri-
mary outcome. QALYs were generated for each participant,
based on health states. These health states were obtained
using the EuroQol-5D-3 L (EQ-5D; [28]), a generic, self-
report instrument. At the start of the trial, this was the
most recent version of the EQ-5D. Utilities for each pos-
sible health state were available from a UK general popula-
tion survey, which is the international standard to valuate
the EQ-5D [29, 30]. Those utilities scores were used as
weights to obtain quality adjusted life years (QALYs) [31].
Economic evaluation
Study perspective and time horizon
The economic evaluation was performed from a societal
perspective, including intervention costs, health care
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(i.e. the period of time evaluated in the analyses [32]) for
this study was 32 weeks, equalling the full assessment
period (eight weeks until end of intervention plus
24 weeks follow-up). As the time horizon was <1 year,
no discounting of costs and effects was necessary (future
costs and benefits were not valued to the present). All
costs were presented in Euro’s and calculated to their
2012 value using price index figures from Statistics
Netherlands [33]. The most recent cost prices that were
available in 2012 (the year the trial ended) were used to
calculate costs.
Costs measures and valuation
In the cost-assessment, we a priori identified health care
costs (See Additional file 3: Tables S1 and S2 for details),
absence from work (absenteeism), and productivity loss at
work (presenteeism) as relevant. Information on costs was
monitored with two self-report instruments assessing
health care consumption, absence from work, and prod-
uctivity loss at work in the past three months. Health care
consumption and medication use were assessed using the
Trimbos/Institute for Medical Technology Assessment
questionnaire for Costs associated with Psychiatric Illness
(TiC-P; [34]); the Productivity and Disease Questionnaire
(PRODISQ; [35, 36]) was used to measure costs of
absence from work and cost of productivity loss at work.
The valuation of health care costs was based on the
updated Dutch Manual for Cost Analysis in Health Care
Research [37]. This manual contains methods and stand-
ard cost prices for economic research in health care.
The costs of medication were based on the Dutch medi-
cation prices [38].
Costs of absenteeism were calculated using the human
capital method by multiplying the number of days
absent with an estimation of the productivity costs per
hour of each participant (obtained from age and gender
specific productivity costs also including an elasticity
factor of 0.8; elasticity to account for the proportional
reduction in productivity resulting from absence from
work) ([37], Table 6.1). Productivity loss (presenteeism)
was calculated using the QQ method, that is 100%
− [quantity of work] × [quality of work] [39, 40]. This
percentage was multiplied by the number of working
hours in 3 months (385 h [37]), because the PRODISQ
was assessed every three months (or data were imputed;
see Statistical analysis).
Intervention costs
Cost calculations of the intervention were based on a
psychologist salary (to translate the researchers time
delivering the intervention to the salary of a health care
professional), which was €173 per hour in 2009 [37],
calculated to the 2012 value of €183.73. ESM-I andpseudo-intervention group participants completed on
average 5.3 (SD = 1.7) and 5.7 (SD = 0.94) intervention
sessions, respectively. Mean duration of these sessions
was 48.9 and 39.5 min. Thus, total time spent per pa-
tient was 4.3 h (€792.62) for ESM-I, and 3.7 h (€689.45)
for the pseudo-intervention.
Willingness-to-pay threshold
In the Netherlands, proportional upper limits exist for
various levels of severity: €20,000 (mild condition),
€50,000 (moderate severe condition), €80,000 (severe
condition) [41]. It is unclear which of these limits would
be most appropriate to set as a maximum willingness to
pay for the QALY for patients with major depression. In
most previous economic evaluations, the willingness-to-
pay threshold for depression was set above this thresh-
old for mild conditions toward the threshold for moder-
ate severe conditions (e.g., [42–44]). Therefore, we set
the willingness-to-pay threshold for ESM-I in major
depression at €50,000 ($59,115).
Statistical analysis
Power calculations using the STATA SAMPSI command
were based on previous work [45], and led to an initial
sample size of 120 with a power of 84% to detect a 3-point
difference in the score on the 17-item HDRS [46, 47], the
primary effectiveness outcome [17]. However, because
many participants were excluded, the inclusion rate was
lower than expected. The eventual number of patients
who participated in the trial was 102.
The economic evaluation consisted of a base-case
cost-effectiveness and cost-utility analysis, and sensitivity
analyses. For the main analysis (base-case), intention-to-
treat (ITT) data were used. All analyses in step 1–4 were
performed using Stata version 13 [48], the economic
evaluation in step 5 was performed using Microsoft
Excel (version 2010).
First, missing observations at the 32-weeks assessment
were replaced by Last Observation Carried Forward; missing
observations at the 20-weeks assessment were replaced by
Next Observation Carried Backward. Second, costs and
QALYs of week 1–8 were estimated by individual mean
imputation of the baseline and the week 20 assessment
(corrected for length of the period by multiplying by 0.667)
to obtain information of the full 32-week period [47]. Subse-
quently, a total cost variable was generated, being the sum
of all above-mentioned costs in the full 32 weeks (base-case
societal perspective). Similarly, QALYs were summed for the
full 32-week period. Third, costs and QALYs over 32-weeks
and HDRS at 32 weeks were analysed using linear regression
analysis to provide background information to the economic
evaluation results. These regression models included
treatment arm as well as baseline values of the dependent
variable (costs, QALYs, and HDRS scores, respectively) as
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participants (intention-to-treat). When costs were the
dependent variable, assumptions for linear regression were
not met and p-values were obtained using permutation ana-
lysis. Fourth, data were prepared for inclusion in the fifth
step (the base-case analyses of the economic evaluation):
costs were controlled for baseline costs using the delta
method [49], i.e., baseline costs were subtracted from total
costs post-assessment. Coefficients obtained from a regres-
sion analysis corrected for baseline costs could not be used
in the present data, because the data failed to meet the
assumption of a normal distribution of the cost residuals,
even after applying methods to address outliers [49] (see also
Methodological considerations). HDRS scores and QALYs
were exported to Excel without further transformations.
For the fifth step, cost and effect pairs per participant were
imported in a previously designed Excel file. Because
residuals in the analysis were not normally distributed, non-
parametric bootstrap resampling techniques were used to
explore sample uncertainty around estimates of the cost-
utility and cost-effectiveness analysis, using the original data
of the three treatment groups. Using this Excel file, 5000
replications were generated. We calculated incremental
cost-effectiveness ratios (ICER) by dividing the incremental
costs by the incremental effects (HDRS scores); by dividing
the incremental costs by the differences in QALYs, we calcu-
lated incremental cost-utility ratios (ICUR). Using the 5000
replications, cost-effectiveness acceptability curves (CEAC)
were generated [31, 50]. For QALYs, an a priori willingness-
to-pay threshold of €50,000 was defined (see above).
Sensitivity analyses
Several one-way sensitivity analyses for deterministic vari-
ables were performed to assess how sensitive results are to
different input values in a priori selected parameters. First,
QALYs were based on the Dutch tariff [51] rather than the
UK tariff [29]. Second, costs for a standard GP-contact
(€29.73 in 2012) were replaced by costs of a psychiatric
GP contact (€60.53) as obtained from the cost manual
[37]. Third, the economic evaluation was performed from
a health care perspective, rather than a societal perspec-
tive. Fourth, complete cases were analysed (as opposed to
intention-to-treat). Finally, analyses were performed when
NOTadjusting for baseline costs.
Results
Participants and baseline characteristics
A total number of 102 participants were randomized to one
of the three treatment arms (see participant flow in Fig. 1).
The intention-to-treat sample consisted of 101 participants
(n= 33 ESM-I, n= 35 pseudo-intervention, n= 33 control
group), given that one participant randomized to the
pseudo-intervention did not fill in any of the assessments
needed for the present analyses, not at baseline, nor atfollow-up. At the 20-week and 32-week follow-up assess-
ments, 86 (85%) and 80 (79%) participants responded,
respectively. Table 1 presents baseline characteristics (see
[17] for more details). At baseline, mean HDRS score was
2 units lower in the ESM-I group than in the control group,
and total costs (societal perspective over 3 months) were
about €450 lower (Table 1). Control group participants more
often had a bipolar disorder, more often had a recent switch
in their antidepressant medication, and less often received
psychotherapy compared with the other two groups;
pseudo-intervention group participants more often had a
comorbid axis I disorder and were more often treated in
primary health care (Table 1).
Costs at the 32-weeks assessment
Intention-to-treat analysis showed that total costs (over
the total 32 weeks; societal perspective) were higher in
the ESM-I group (€17,957) than in the control group
(€16,216) and the pseudo-intervention group (€16,816;
Table 2). However, these differences were not statistically
significant after adjustment for baseline costs (Table 2,
last two columns; Additional file 3: Table S1). There
were also no statistically significant differences between
ESM-I and the control groups in any of the cost categories
separately (Table 2).
HDRS and QALYs at the 32-weeks assessment
At 32 weeks, mean HDRS score was three units lower in
the ESM-I group than in the control group (after adjustment
for baseline HDRS scores), which was statistically imprecise
by conventional alpha (Table 3; B =−3.1, p= 0.051,
intention-to-treat analysis). The ESM-I and the pseudo-
intervention group did not differ (B =−1.13, p= 0.47). There
was no evidence that ESM-I participants were more often in
symptomatic remission compared with control group partic-
ipants (OR= 2.65, p= 0.12); ESM-I participants did not
differ in the rate of symptomatic remission compared with
the pseudo-intervention participants (OR= 1.84, p= 0.29).
QALYs were higher in the ESM-I group than in the
control group (B = 0.08, p = 0.01, Table 3), but the differ-
ence between ESM-I and pseudo-intervention group was
not statistically significant (B = 0.04, p = 0.15).
Cost-effectiveness and cost-utility analysis (time horizon
32 weeks)
In the cost-effectiveness analysis (outcome: HDRS), ESM-
I had the highest probability of being cost-effective com-
pared with treatment as usual and pseudo-intervention
when willingness to pay was over €4000 ranging from a
probability of 10 to 86% (when willingness to pay is €0
and €37,500 respectively; Fig. 2). Note that the treatment
with the highest probability of cost-effectiveness is the
upper line in the figure at each level of willingness to pay.
Fig. 1 Flow diagram of the study. ESM = Experience Sampling Method; TAU = treatment as usual HDRS – 17-item Hamilton Depression Rating
Scale; EQ-5D – EuroQol-5D-3 L; TiC-P – Trimbos/IMTA questionnaire for Costs associated with Psychiatric Illness; PRODISQ – The Productivity and
Disease Questionnaire
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CEAC curve showed that ESM-I had the highest prob-
ability of being the most optimal of the three treatments
when willingness to pay was over €40,500 (Fig. 3). At the
a priori willingness-to-pay threshold of €50,000, ESM-I
was the intervention with the highest probability of
being cost effective (ESM-I 46%, pseudo-intervention
34%, treatment as usual 20%).
Sensitivity analyses
Table 4 presents both the base-case and sensitivity cost-
effectiveness and cost-utility results. When willingness to
pay levels were higher than between €30,000 and €40,000,
ESM-I was the most optimal treatment (Table 4, Fig. 2,
Additional file 4: Figure S1, Additional file 5: Figure S2,Additional file 6: Figure S3 and Additional file 7: Figure S4)
in the cost effectiveness analyses (HDRS). The sensitivity
analysis from the health care perspective and the complete
cases analysis were more optimistic than the base-case
analysis, being most cost effective from €3000 and
€3750, respectively.
At the willingness-to-pay threshold of €50,000, the
probability that ESM-I is most cost-effective was between
44 and 65% (cost utility analysis, Table 4, Figs. 3 and 4 and
Additional file 8: Figure S5, Additional file 9: Figure S6,
Additional file 10: Figure S7 and Additional file 11:
Figure S8). Again, the sensitivity analysis from the
health care perspective and the complete cases ana-
lysis were most optimistic with percentages of 64 and
65% at the willingness-to-pay threshold of €50,000.
Table 2 Costs over 32 weeks (intention-to-treat)
ESM-I (n = 33) Pseudo-intervention (n = 35) Control (n = 33) Regression coefficients; B
(p-value obtained from permutation analyses)
M (SD) M (SD) M (SD) ESM-I vs Control ESM-I vs Pseudo-intervention
Health care use (total)a €6751 (€19420) €6510 (€7315) €6520 (€14082) -€165 (p = 0.96) €1818 (p = 0.66)
Medication €104 (€296) €25 (€56) €75 (€171) €12 (p = 0.82) €36 (p = 0.54)
Total health costsb €7648 (€19402) €7225 (€7304) €6596 (€14072) €640 (p = 0.80) €1957 (p = 0.61)
Societal
Absence from work €6067 (€13691) €4732 (€9372) €5379 (€11889) €945 (p = 0.74) €857 (p = 0.75)
Productivity loss at work €4234 (€7721) €4858 (€8438) €4241 (€7627) €605 (p = 0.76) -€594 (p = 0.80)
Total €17957 (€31329) €16816 (€17595) €16216 (€27756) €2483 (p = 0.74) €2152 (p = 0.75)
aSeveral types of health care consumption see Additional file 3: Table S1
bIncluding intervention costs in ESM-I and pseudo-intervention group
Table 1 Baseline characteristics
ESM-I (n = 33) Pseudo-intervention (n = 35) Control group (n = 33)
Gender, male: n (%) 17 (51.5) 14 (40.0) 15 (45.5)
Age, years: mean (SD) 49 (10.2) 47 (9.7) 49 (10.9)
Education
low (no/primary/low secondary) 6 (18.1) 9 (25.7) 10 (30.3)
medium (high school/low vocational) 12 (36.4) 14 (40.0) 12 (36.3)
high (higher vocational/university) 15 (45.5) 12 (34.3) 11 (33.3)
Depressive symptoms (HDRS): mean (SD) 13.5 (5.6) 15.1 (6.9) 15.5 (5.4)
range 2–30 2–30 5–27
Treated in primary care 7 (21) 6 (17) 8 (24)
Bipolar disorder 2 (6) 2 (6) 5 (15)
DSM-IV axis I comorbidity 12 (36) 16 (46) 12 (36)
Psychotherapy yes/no 4 (15) 4 (13) 2 (7)
Use of antidepressant medicationa
New 2 (6) 3 (9) 1 (3)
Switch 3 (9) 3 (9) 7 (21)
Maintenance 28 (85) 29 (83) 25 (76)
QALYs, last 12 weeks, mean (SD)
EQ-5D, UK tariff (Dolan) (range − 0.04; 0.23) 0.15 (0.07) 0.14 (0.06) 0.12 (0.07)
Health care costs (last 12 weeks), mean (SD)
Health care use €2230 (€7186) €3150 (€4369) €1999 (€4348)
Medication €42 (€145) €18 (€59) €32 (€79)
Total €2273 (€7179) €3168 (€4363) €2032 (€4342)
Societal (last 12 weeks), mean (SD)
Absence from work €2541 (€5983) €2154 (€4852) €2785 (€5066)
Productivity loss at work €2156 (€3910) €2135 (€3486) €2637 (€4224)
Total (incl. health care costs) €6828 (€12817) €7458 (€10201) €7291 (€9360)
HDRS 17-item Hamilton Depression Rating Scale, QALY quality adjusted life year, EQ-5D EuroQol-5D-3L
aNew and switch are defined as shorter than 8 weeks on this medication; the rest is maintenance
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Regression coefficients; B (95% confidence interval)a
ESM-I vs Control ESM-I vs Pseudo-intervention
HDRS (at 32 weeks)
HDRS scorea 10.8 (7.1) 13 (7.12) 15.3 (8.3) −3.1 (−6.2; 0.01) −1.13 (−4.18; 1.92)
Improvement since baseline 2.7 (6.1) 2.1 (5.9) 0.24 (7.5) 3.1 (−0.01; 6.2) 1.13 (−1.92; 4.18)
Symptomatic remissionb 11 (33.3) 9 (25.7) 6 (18.2) OR = 2.65 (0.79; 8.9) OR = 1.84 (0.59; 5.7)
QALYs (over 32 weeks)
EQ-5D, UK tariff 0.45 (0.17) 0.38 (0.18) 0.32 (0.18) 0.08 (0.02; 0.10)* 0.04 (−0.02; 0.10)
HDRS 17-item Hamilton Depression Rating Scale, QALY quality adjusted life year, EQ-5D EuroQol-5D-3L
*p < 0.05
aControlled for baseline values
bSymptomatic remission = HDRS score ≤ 7
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Key findings
The present study provides, to our knowledge, the first eco-
nomic evaluation of an intervention using ESM in patients
with major depression. The results suggest that ESM-I is
more expensive, but also more clinically effective than both
treatment as usual and pseudo-intervention.
In the cost-effectiveness analysis and cost-utility ana-
lysis, ESM-I was the most optimal strategy when willing-
ness to pay was over €3000 and €40,500, respectively. All
sensitivity analyses except one were similar to the base-
case analysis. That one exception, that is the analysis
unadjusted for baseline costs, had lower willingness to
pay, and a probability of cost-effectiveness at €50,000 ofFig. 2 Cost-effectiveness acceptability curve of the base-case
analysis, assessing the Hamilton Depression Rating Scale. The analysis
was controlled for baseline costs. The lines per treatment indicate
the probability (y-axis), i.e., the proportion of replications this
treatment has the highest net monetary benefit given various levels
of willingness to pay (x-axis). At those willingness-to-pay levels where
ESM-I has the higher probability compared with the other two
treatments (summing up to 100%), ESM-I is the most cost-effective
option. TAU= treatment as usual (control group); PSEUDO=pseudo-
intervention group; ESM-I = ESM-intervention group58%. In addition, CEAC showed that ESM-I cost-
effectiveness probability increased rapidly towards the
most favourable treatment.
Furthermore, although costs are below the threshold
set for a QALY (€50,000), such a threshold could not be
defined for the HDRS. Therefore, we can only tentatively
conclude that ESM-I is cost-effective.Cost-effectiveness of ESM-I in real life major depression
treatment
The present trial shows that ESM-I consisting of pro-
tocolled feedback delivered by a researcher has the
potential to be cost-effective. When implementing
ESM-I in real life treatment, feedback can be deliv-
ered directly to the patient and professional caregiver.
Feasibility and cost-effectiveness are hypothesized to
increase when the option of feedback provided by a
third person (the researcher) is replaced with ESM-I
feedback that forms an integral part of the treatment.
ESM-I could then also be used to enrich psycho-
logical treatments such as cognitive behaviour therapy
[52] with daily life contextual information and to
bring that therapy out of the mental health care
setting into daily life. Our six-week ESM intervention
has been shown feasible in outpatients with major
depression [17], but the feasibility of implementation
in routine clinical practise is not yet established [13].
Web-based feedback systems for ESM-I applications
are under development. If such a web-based system
allows individuals to navigate through their own feed-
back, this may facilitate implementation of the current
ESM intervention by promoting easy access to and flex-
ible use of feedback for patients as well as professional
caregivers. This should be backed up by appropriate
resources for professional caregivers including training,
monitoring, and technical support [53]. In addition,
withdrawal of the professional caregiver and patient
disengagement may be an important issue, requiring
research to improve sustained use [54].
Fig. 3 Cost-effectiveness acceptability curve of the base-case analysis, assessing the EQ-5D. The analysis was controlled for baseline costs. The analysis
was controlled for baseline costs with the bootstrapped societal costs and EQ-5D-based QALYs. The lines per treatment indicate the probability (y-axis),
i.e., the proportion of replications this treatment has the highest net monetary benefit, given various levels of willingness to pay (x-axis). At those
willingness-to-pay levels where ESM-I has the higher probability compared with the other two treatments (summing up to 100%), ESM-I is the most
cost-effective option. At the willingness-to-pay threshold of €50,000, the probability is 46% for ESM-I, which is higher compared with TAU (20%) and
Pseudo (34%). TAU = treatment as usual (control group); PSEUDO = pseudo-intervention group; ESM-I = ESM-intervention group
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The ESM-I group showed lower HDRS scores at 32-weeks
than the two control groups, suggesting that ESM-I
reduced depressive symptoms. However, although the
economic evaluation showed that ESM-I may be cost-Table 4 Results of base-case and sensitivity analyses of the cost-util
compared with both control conditions




Different GP cost calculation 3000
Health care perspective 1500
Complete cases 2250
NOT controlling for baseline costs 1250
QALY €
Base-case analysis 31, 500
Dutch instead of UK tariff 32, 500
Different GP cost calculation 30, 500
Health care perspective 16, 500
Complete cases 23, 500
NOT controlling for baseline costs 11, 500
aThe probability that ESM-I is most cost-effective at the willingness-to-pay threshold
bA value of €0 indicates that ESM-I is dominant compared with the other interventi
with the other treatmenteffective, in the accompanying regression analyses (HDRS
and QALYs; Table 3), the difference between the ESM-I
and the pseudo-intervention group was not statistically
significant while the difference between ESM-I and con-
trol group was statistically imprecise by conventionality and cost-effectiveness analyses: willingness to pay when
















on, i.e., ESM-I shows more improvement in outcomes at lower costs compared
Fig. 4 Cost-effectiveness acceptability curve of a sensitivity analysis assessing the EQ-5D: unadjusted for baseline costs
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nomic evaluation [17], did show that allocation to ESM-I
was associated with a statistically significant linear
decrease in HDRS depressive symptoms over time that
lasted throughout the study. This decrease was signifi-
cantly stronger than in the control group to a degree that
can be considered clinically relevant (difference > 3
HDRS units; [46, 47]). The difference with the
pseudo-experimental group was clinically relevant and
borderline significant [17]. For the regression analysis
results accompanying the cost effectiveness results in
the present paper, less data were used than in the
original analyses which included all follow-up assess-
ments. In addition, the original paper analysed
subjects as randomized with available data while the
present paper imputed data (using last observation
carried forward).
Cost-effectiveness and severity of depression
The study sample consisted of patients with a major
depression with current symptoms in the mild to severe
range, including residual depressive states. Given that
meta-analytic evidence suggests that the efficacy of psy-
chotherapeutic interventions may be larger in patients
with higher levels of pre-treatment depressive symptoms
[55], a subgroup analysis only including patients with se-
vere or very severe depressive symptoms was warranted.
However, in the present data, the number of patients insubgroups (e.g. only 20 patients with HDRS ≥ 19) was
too low to obtain valid results. Future economic evalua-
tions of ESM-I should include sufficient numbers of
patients at each level of severity to enable subgroup
analysis in patients with mild/moderate and with severe/
very severe symptoms separately.
Methodological considerations
The present study was limited to patients aged between
18 and 65 years (mean age 48 years) and more than 90%
of the sample was from Dutch origin. ESM-I is designed
to obtain insights in everyday life and, therefore, we
recruited outpatients that could engage in ESM self-
monitoring in their home environment. Outpatients
were included in the study if they scored above remis-
sion level (HDRS > 7) at study entrance. This mild inclu-
sion criterion, coupled with the time intensive nature of
the study protocol (multiple visits to the researcher on
top of an intensive intervention consisting of 6 weeks of
self-monitoring), may have led to recruiting mainly par-
ticipants in a mild to moderate depressive state. How-
ever, this may be a rather accurate representation of the
population of patients with major depression, of which the
majority experiences mild to moderate symptoms, and
using higher HDRS cut-offs would compromise the exter-
nal validity of the trial [56, 57]. On the other hand, our
sample was mostly recruited from specialised mental
health care settings (approximately 20% was treated in
Simons et al. BMC Psychiatry  (2017) 17:415 Page 11 of 14primary care only), and had a diagnosis of major depres-
sion as well as current symptoms for which they were
using antidepressants. Although the results may not be
generalizable to all outpatients with major depression,
they may be generalizable to outpatients with complex
mental problems who are using antidepressants.
The present paper has several limitations. First, owing to
the nature of the intervention, it was not possible to blind
participants and the use of envelopes could potentially have
led to biased allocation. However, given that care-providers
were not involved in the randomization process and most
envelopes were drawn from a distance, with one researcher
drawing an envelope for another researcher, it is unlikely
that subversions to the procedure took place. Researchers
conducting the post-intervention assessments were also not
blind to treatment allocation due to resource constraints.
Thus findings may reflect a placebo response. However, the
effect study [17] showed that directly after the six-week
intervention, the decrease in HDRS ratings was similar in
the ESM-I group and the pseudo-intervention group, while
in the pseudo-intervention group effects did not appear to
persist during the full 32-weeks of the trial. It is often
assumed that placebo effects in depression do not persist in
the long run [58]. Although, this belief has been falsified
[58], the difference in persistence between the pseudo-
intervention group and the ESM-I group may evidence that
it is unlikely that our findings are completely attributable to
a placebo effect. The improvement in the ESM-I group
showed a persistent, steady and clinically relevant growth
over time in the full 32 weeks, further making the possibil-
ity of a placebo effect even more unlikely.
Second, all three treatment arms were embedded in an
extensive research protocol, including regular assessment of
depressive symptoms and two five-day ESM assessments.
Besides treatment effects, patients may have had non-
specific benefits from self-monitoring. Therefore, what has
been called treatment as usual in the present paper, strictly
is not. ESM-I may be even more cost-effective when com-
pared with true treatment as usual.
Third, we used the human capital method rather than
the friction costs method to calculate work absence costs,
because the PRODISQ absenteeism module only asked
number of absent days during a period of 3 months, while
friction period was longer at the time of data collection
(approximately 5 months) [37]. Therefore, end of the
friction period could not be identified.
Fourth, sampling uncertainty was estimated using the
non-parametric bootstrapping approach. Alternatively,
another common approach for the handling of trial-
based data would have been to estimate the mean total
costs per treatment condition using a GLM that assumes
a Gamma distribution for costs (i.e., to accommodate
the skewness in the distribution of costs). This would
also allow for the regression-based adjustment of costestimates through the inclusion of possible covariates in
the GLM. It could therefore be considered a limitation
that non-adjusted costs were reported.
Fifth, sample sizes for the present study were rather small.
Results need to be replicated in studies with larger sample
sizes. However, other economic evaluations are also per-
formed using small sample sizes. Sensitivity analyses and
bootstrapping are required to correct for sampling uncer-
tainty and to prevent chance findings. As expected, costs
were not normally distributed and, therefore, a condition for
regression was not met (normal distribution of the resid-
uals). We therefore performed non-parametric bootstrap
resampling. However, baseline costs were also skewed and
had outliers, and regressing baseline costs onto total costs
[49] resulted in non-normal distribution of residuals, even
after transformation to the natural logarithm. Several
methods to deal with the problem of outliers have been
advocated [49]. However, removing various percentages (2,
5, 10, 20, or 30%) of observations at the extremes, resulted
in non-normally distributed residuals and in inconsistent re-
gression coefficients of baseline costs (B = 0.84, 0.82, 0.79,
0.72, 0.66, respectively; base-case analyses: B = 0.86). There-
fore, the best option to correct for baseline costs [49] was
impossible in the present data, and it is most prudent to per-
form the delta method to control for baseline costs rather
than regression-based adjustment [49] (see also Methods).
Furthermore, we chose for easy methods to deal with
missing data because the number of missings was limited.
The proportion of missing values was not significantly asso-
ciated with treatment allocation, nor with baseline and pre-
vious observed depression scores or baseline demographics.
Last observation carried forward, next observation carried
backward, and mean imputation have been shown to
perform as good as multiple imputation [59].
Finally, of all parameters that we varied in the sensitivity
analyses, correction for baseline costs was the only factor
that changed the willingness to pay, but probability of
cost-effectiveness at the a priori threshold of €50,000
remained similar to the base-case analysis. Correction for
baseline costs is relatively new in economic evaluations, in
contrast to epidemiology and statistics, were controlling
for baseline differences is standard practise to get valid
results [60]. The present results show that the impact of
controlling for baseline may be considerable and suggest
that, as in other fields of research, results without baseline
correction may be invalid.Conclusion
We may tentatively conclude that ESM-I is cost-effective
in outpatients with major depression. Only tentatively
because the probability that ESM-I was cost effective
was only 44% at the predefined threshold of €50,000,
while no threshold for the HDRS could be defined.
Simons et al. BMC Psychiatry  (2017) 17:415 Page 12 of 14Future studies are needed to replicate the present findings
and to study patients with severe depressive symptoms sep-
arately. If future research replicates effectiveness and cost-
effectiveness, we would recommend ESM-I as an addition
to psychopharmacological treatment as usual. Integration of
ESM-I in psychological treatment is also a possibility.Additional files
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